一名肺动脉高压患者出现与西他生坦相关的急性肝衰竭。 - Suppr

Suppr

超能文献

Sitaxentan-related acute liver failure in a patient with pulmonary arterial hypertension.

作者信息

Lee W-T N, Kirkham N, Johnson M K, Lordan J L, Fisher A J, Peacock A J

出版信息

Eur Respir J. 2011 Feb;37(2):472-4. doi: 10.1183/09031936.00091610.

DOI:10.1183/09031936.00091610

PMID:21282815

Abstract

摘要

相似文献

Eur Respir J. 2011 Feb;37(2):472-4. doi: 10.1183/09031936.00091610.

Liver toxicity of sitaxentan in pulmonary arterial hypertension.西他生坦在肺动脉高压中的肝毒性。

Eur Respir J. 2011 Feb;37(2):475-6. doi: 10.1183/09031936.00194810.

Liver toxicity of sitaxentan in pulmonary arterial hypertension.

Eur Heart J. 2011 Feb;32(4):386-7.

Ironic case of hepatic dysfunction following the global withdrawal of sitaxentan.西他生坦全球撤市后肝功能异常的罕见病例报告。

Intern Med J. 2012 Dec;42(12):1351-4. doi: 10.1111/imj.12007.

Sitaxentan-induced hepatic failure in two patients with pulmonary arterial hypertension.

Eur Respir J. 2009 Sep;34(3):770-1. doi: 10.1183/09031936.00058409.

[Endothelin receptor antagonists in the new European guidelines on pulmonary hypertension].[内皮素受体拮抗剂在欧洲肺动脉高压新指南中的应用]

Rev Mal Respir. 2010 Feb;27(2):103-5. doi: 10.1016/j.rmr.2009.12.007. Epub 2010 Jan 25.

Successful up-front combination therapy in a patient with idiopathic pulmonary hypertension and patent foramen ovale: an alternative to epoprostenol therapy?一名特发性肺动脉高压合并卵圆孔未闭患者的成功初始联合治疗：依前列醇治疗的替代方案？

J Heart Lung Transplant. 2009 Jun;28(6):651-3. doi: 10.1016/j.healun.2009.03.009.

Pulmonary arterial hypertension occurrence after liver transplant in systemic sclerosis: a report of 2 cases sustainably treated by sildenafil.系统性硬皮病患者肝移植后发生肺动脉高压：2 例应用西地那非持续治疗的报告。

Clin Exp Rheumatol. 2010 Mar-Apr;28(2 Suppl 58):S53-4. Epub 2010 Jun 10.

[Pulmonary hypertension treatment: future prospects].[肺动脉高压治疗：未来前景]

Arch Bronconeumol. 2007 Mar;43(3):131-5. doi: 10.1016/s1579-2129(07)60036-6.

An evidence-based approach to the management of pulmonary arterial hypertension.

Curr Opin Cardiol. 2006 Sep;21(5):526; author reply 526-7. doi: 10.1097/01.hco.0000240592.44957.4b.

引用本文的文献

Liver injury due to endothelin receptor antagonists: a real-world study based on post-marketing drug monitoring data.内皮素受体拮抗剂致肝损伤：基于上市后药物监测数据的真实世界研究。

Ther Adv Respir Dis. 2024 Jan-Dec;18:17534666231223606. doi: 10.1177/17534666231223606.

Microphysiological Models for Mechanistic-Based Prediction of Idiosyncratic DILI.基于机制的药物性肝损伤个体化预测的微生理模型。

Cells. 2023 May 25;12(11):1476. doi: 10.3390/cells12111476.

New Drugs and Therapies in Pulmonary Arterial Hypertension.新型药物和疗法在肺动脉高压中的应用。

Int J Mol Sci. 2023 Mar 19;24(6):5850. doi: 10.3390/ijms24065850.

A narrative review on adverse effects of dasatinib with a focus on pharmacotherapy of dasatinib-induced pulmonary toxicities.一篇关于达沙替尼不良反应的叙述性综述，重点关注达沙替尼诱导的肺部毒性的药物治疗。

Blood Res. 2021 Dec 31;56(4):229-242. doi: 10.5045/br.2021.2021117.

Endothelin Blockade in Diabetic Kidney Disease.糖尿病肾病中的内皮素阻断

J Clin Med. 2015 May 25;4(6):1171-92. doi: 10.3390/jcm4061171.

Effectiveness of phosphodiesterase-5 inhibitor therapy for portopulmonary hypertension.磷酸二酯酶-5抑制剂治疗门脉性肺动脉高压的疗效

Can Respir J. 2015 Jan-Feb;22(1):42-6. doi: 10.1155/2015/810376. Epub 2014 Dec 18.

Treatment of pulmonary arterial hypertension with targeted therapies.肺动脉高压的靶向治疗。

Nat Rev Cardiol. 2011 Jul 19;8(9):526-38. doi: 10.1038/nrcardio.2011.104.

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验